Press release
Investors in shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) should contact the Shareholders Foundation
An investigation for investors in Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares over potential securities laws violations.
Investors who purchased shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) in mid 2019 or earlier and continue to hold any of their NASDAQ: AVTX shares, have certain options. Please contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Avalo Therapeutics, Inc. (NASDAQ: AVTX) concerning whether a series of statements by Avalo Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Rockville, MD based Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
Shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) declined from $5.71 per share in December 2019 to as low as $1.7 per share in March 2020.
Avalo Therapeutics, Inc. reported that its annual Total Revenue declined from $6.75 million in 2019 to $6.69 million in 2020, and that its Net Loss increased from $16.07 million in 2019 to $63.50 million in 2020.
On December 9, 2021, NASDAQ: AVTX shares closed on $1.92 per share.
Those who purchased shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors in shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) should contact the Shareholders Foundation here
News-ID: 2492535 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Avalo
Chronic Refractory Cough Market Forecasted to Surge in Coming Years, 2024-2034 A …
The Key Chronic Refractory Cough Companies in the market include - Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others.
DelveInsight's "Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the…
Phosphoglucomutase (PGM 1) Deficiency Market Scope and Competitive Analysis Fore …
The Phosphoglucomutase (PGM 1) Deficiency Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/phosphoglucomutase-deficiency-market
What is…
Chronic Refractory Cough Market Report 2032: Epidemiology Data, Pipeline Therapi …
The Chronic Refractory Cough Market size was valued USD 8,7845 Million in 2022 and the report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the 7MM.
DelveInsight's "Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory…
Asthma Pipeline Insights Report 2024 | GlaxoSmithKline, Immunotek SL, AB Science …
DelveInsight's, "Asthma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Asthma Pipeline Report
• DelveInsight's Asthma pipeline…
Avalo Therapeutics, Inc. (NASDAQ: AVTX) Investor Noitce: Investigation over pote …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Avalo Therapeutics, Inc f.k.a. Cerecor Inc.
Investors who purchased shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Avalo Therapeutics, Inc. officers and directors breached their fiduciary duties and caused damage to…
Investigation announced for Long-Term Investors in Avalo Therapeutics, Inc. (NAS …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Avalo Therapeutics, Inc f.k.a. Cerecor Inc.
Investors who purchased shares of Avalo Therapeutics, Inc. (NASDAQ: AVTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Avalo Therapeutics, Inc. officers and directors breached their fiduciary duties and caused damage to…
